Functionally, GLP-1R activation by its endogenous agonist GLP-1 promotes insulin secretion, suppresses glucagon release, slows gastric emptying, and induces satiety, thereby making it a pivotal therapeutic target in type 2 diabetes mellitus (T2DM) and obesity. This evidence concerns the gene INS and diabetes mellitus.